Korro Bio, Inc. - Common Stock (KRRO)
38.08
+0.58 (1.55%)
NASDAQ · Last Trade: Oct 24th, 12:24 PM EDT

Industry veterans John Maraganore, Ph.D., and Rachel Meyers, Ph.D., to provide strategic guidance on the company’s RNA Actuating platform to develop a new class of RNA medicines that upregulate protein coding genes
By CAMP4 Therapeutics · Via GlobeNewswire · December 10, 2024

The European Central Bank cut interest rates for the second time in about three months prior the FOMC's interest rate announcement, European stocks may benefit.
Via MarketBeat · September 22, 2024